Data for this Review included all available clinical studies addressing vaccine effectiveness against influenza-related mortality in elderly people. We also relied on the compilation of studies identified in a recent Cochrane review of clinical trials and observational studies in elderly people, and several meta-analyses of observational studies done in recent decades in community-living elderly people and nursing-home populations. Because no clinical trials studied mortality outcomes, we
ReviewMortality benefits of influenza vaccination in elderly people: an ongoing controversy
Introduction
Influenza epidemics occur almost every winter in the USA. These epidemics cause illness in about 5–20% of the US population,1, 2 and lead to approximately 300 000 influenza-related hospital admissions and 36 000 influenza-related deaths annually.3, 4 Except during pandemic seasons, about 90% of all influenza-related deaths occur among people aged at least 65 years.5, 6
Influenza vaccines have convincingly been shown to be effective in preventing influenza infection in healthy adults.7 In 1960, US health authorities adopted a policy of targeting influenza vaccination efforts to those at high risk for severe outcomes, including people with chronic conditions and elderly people.8, 9, 10 Similar policies have been adopted in most other high-income countries and have been endorsed by WHO.11 Vaccination coverage of US elderly people has risen substantially in recent decades, from approximately 15% in 1980 to approximately 65% by the mid-1990s.12
Although current policy emphasises vaccination of elderly people, the evidence that this strategy effectively reduces influenza-related mortality in that age-group is weak. Placebo-controlled randomised clinical trial (RCT) data indicate that vaccination effectively prevents influenza illness in younger, healthy elderly people, but no RCT data conclusively show a similar benefit in those aged 70 years or more, the age-group that accounts for nearly all influenza-related deaths.
In the absence of so-called gold-standard RCT data, the evidence base consists mainly of observational studies that compare mortality risks in self-selected groups of vaccinated and unvaccinated elderly people. Many of these studies have concluded that vaccination reduces winter-season mortality from any cause by approximately 50% in community-dwelling elderly people,13 and even more in nursing-home populations.14 However, such astonishing mortality benefits are simply not consistent with estimates of the influenza-related mortality burden among elderly people, as derived from national vital statistics data.6, 15
In this Review, we examine the major findings of, and inconsistencies between, the various kinds of evidence regarding mortality benefits of influenza vaccination of elderly people. We argue that unrecognised selection bias has led cohort studies to greatly overestimate mortality benefits. The remaining evidence is not sufficient to show that vaccination substantially reduces the risk of influenza-related mortality among elderly people. We propose a framework for identifying residual bias in cohort studies, which should help to provide a clearer picture of what vaccine mortality benefits can and cannot reasonably be expected. Our objective is to move towards a better evidence base for the setting of priorities for influenza vaccination and to identify areas where further research is needed.
Section snippets
National excess mortality studies and assessment of influenza-related mortality
Assessment of the number of influenza-related deaths in elderly people is a difficult task, for many reasons. What is diagnosed as an influenza-like illness is often caused by a respiratory virus other than influenza. Moreover, influenza is often a precipitating factor that brings about death from secondary bacterial pneumonia or underlying chronic disorders,16, 17 which are usually identified as the cause of death.
Influenza-related mortality is therefore traditionally assessed by use of an
Randomised placebo-controlled clinical trials
Few placebo-controlled RCTs of influenza vaccine efficacy in elderly people have been done, and none have been powered to study severe outcomes, including mortality. However, because of the importance of this gold-standard type of evidence, we do include RCTs with morbidity endpoints in this Review. With the exception of one small trial,25 placebo-controlled trials comprised healthy, relatively young, elderly people.26, 27, 28 This fact severely limits what such RCTs can tell us about vaccine
Cohort studies of influenza vaccine benefits
Cohort studies of influenza vaccine effectiveness can be divided into two distinct types. Before 1990, cohort studies were usually prospective and done in nursing homes, had laboratory-confirmed primary endpoints, and used laboratory surveillance data to define the influenza season. Additionally, these earlier cohort studies often reported on less specific outcomes, such as death from any cause, even though the number of deaths among study participants tended to be small. A quantitative review
Towards a stronger evidence base
We have argued that cohort studies asserting that influenza vaccination can reduce winter mortality by approximately 50% cannot possibly be correct. This problem was also highlighted in a recent Cochrane review and an editorial.36, 44 We suggest two factors have caused this substantial mismeasurement.
The first of these is frailty selection. We hypothesise that a small subset of under-vaccinated and very frail elderly people contributed a substantial proportion of the total winter deaths
Conclusions
Between the paucity of RCT data and the problematic cohort studies done to date, the evidence base for mortality benefits of influenza vaccination in older elderly people is slim and not particularly encouraging with regard to the degree to which influenza vaccination protects elderly people against severe influenza outcomes. Govaert and colleagues27 suggested that vaccine effectiveness declines sharply after age 70 years. Data from a study by Falsey and colleagues54 suggested a vaccine
Search strategy and selection criteria
References (62)
- et al.
A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community
Vaccine
(2002) - et al.
Influenza-related mortality in the Italian elderly: no decline associated with increasing vaccination coverage
Vaccine
(2006) - et al.
Is influenza vaccination cost effective for healthy people between ages 65 and 74 years? A randomised controlled trial
Vaccine
(2004) Immune remodeling: lessons from repertoire alterations during chronological aging and in immune-mediated disease
Trends Mol Med
(2007)- et al.
Immune response to influenza vaccination of elderly people. A randomized double-blind placebo-controlled trial
Vaccine
(1994) - et al.
Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review
Lancet
(2005) The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines
Vaccine
(2003)Antiflu, or antideath vaccination?
Lancet
(2001)- et al.
Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons
Vaccine
(1999) Epidemiological and clinical aspects of influenza
(1982)
Epidemiology of influenza
Mortality associated with influenza and respiratory syncytial virus in the United States
JAMA
Influenza-associated hospitalizations in the United States
JAMA
Pandemic versus epidemic influenza mortality: a pattern of changing age distribution
J Infect Dis
Impact of influenza vaccination on seasonal mortality in the US elderly population
Arch Intern Med
Vaccines for preventing influenza in healthy adults
Cochrane Database Syst Rev
Influenza immunization
J Okla State Med Assoc
Evaluation of monovalent influenza vaccine in a retirement community during the epidemic of 1965–66
JAMA
Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP)
MMWR Recomm Rep
Prevention and control of influenza pandemics and annual epidemics. Resolution 56.19
Racial/ethnic disparities in influenza and pneumococcal vaccination levels among persons aged > or =65 years—United States, 1989–2001
MMWR Morb Mortal Wkly Rep
The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature
Ann Intern Med
Impact of respiratory virus infections on persons with chronic underlying conditions
JAMA
Influenza and the winter increase in mortality in the United States, 1959–1999
Am J Epidemiol
The epidemiological basis for the control of influenza
Am J Public Health Nations Health
Methods for current statistical analysis of excess pneumonia-influenza deaths
Public Health Rep
The impact of influenza epidemics on mortality: introducing a severity index
Am J Public Health
Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial
JAMA
Should we question the benefits of influenza vaccination for the elderly?
Infect Dis News
Global reduction of Hib disease: what are the next steps? Proceedings of the meeting Scottsdale, Arizona, September 22–25, 2002
J Pediatr
Influenza vaccination and mortality in the United States
Arch Intern Med
Cited by (463)
A safety study evaluating non-COVID-19 mortality risk following COVID-19 vaccination
2023, VaccineCitation Excerpt :The associations that we found between COVID-19 vaccination and non-COVID-19 mortality are stronger than can plausibly be attributed to any real protective effect of vaccination. A more convincing explanation is selection bias as has been reported in studies of influenza vaccination and mortality.[18,19,40,41] Selection bias can arise as patients who anticipate that they are near death “give up” on vaccinations as they are near death and they tend to become less willing and able to seek vaccinations and other preventive services.
Influenza vaccination mitigates severe complications in hospitalized patients: A ten-year observational study, Spain, 2009-2019
2023, American Journal of Infection Control